Nassif ME, Qintar M, Windsor SL, et al. - Given that not only heart failure (HF) hospitalizations are prevented in Type 2 Diabetes (T2D) cases but also improved results in cases with HF and reduced ejection fraction (EF) are provided, irrespective of T2D, by sodium glucose cotransporter 2 inhibitors (SGLT2i), so, researchers sought to clarify mechanisms of HF benefits and examined the impacts of SGLT2i on hemodynamics (filling pressures) in an investigator-initiated, randomized, multi-center, double-blind, placebo-controlled trial (EMBRACE-HF Trial). HF patients (irrespective of EF, with or without T2D) and previously implanted pulmonary artery (PA) pressure sensor (CardioMEMS) were randomly assigned to empagliflozin 10 mg daily or placebo and received treatment for 12 weeks. Alteration in PA diastolic pressure from baseline to finish of treatment was assessed as primary endpoint. Findings revealed that treatment with empagliflozin, in patients with HF and CardioMEMS PA pressure sensor, resulted in quick decreases in PA pressures that were amplified over time and seemed to be independent of loop diuretic treatment.